Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Condition(s):Luminal BLast Updated:March 15, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Luminal BLast Updated:March 15, 2024Active, not recruiting
Condition(s):Lung Cancer; Extensive-stage Small-cell Lung Cancer; RadiotherapyLast Updated:August 5, 2022Not yet recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:February 15, 2024Terminated
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:February 5, 2020Unknown status
Condition(s):Oropharyngeal Squamous Cell CarcinomaLast Updated:February 17, 2023Completed
Condition(s):Non-small Cell Lung Cancer Stage IIILast Updated:September 13, 2023Not yet recruiting
Condition(s):Locally Advanced Lung Non-Small Cell Carcinoma; Locally Recurrent Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell CarcinomaLast Updated:March 7, 2024Recruiting
Condition(s):Colorectal Cancer; Liver MetastasesLast Updated:May 31, 2022Completed
Condition(s):Colorectal Cancer MetastaticLast Updated:December 5, 2022Completed
Condition(s):Adenocarcinoma of the PancreasLast Updated:October 12, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.